# Lumira Ventures Lumira Ventures is a Venture Capital based in Toronto, Ontario, Canada. ## Overview - **Organization type:** Venture Capital - **Headquarters:** Toronto, Ontario, Canada - **Region:** North America - **Address:** Toronto, ON, Canada - **Founded:** 1989 - **Assets under management:** Undisclosed - **Website:** lumiraventures.com - **LinkedIn:** https://www.linkedin.com/company/lumiraventures ## Regulatory record - **CRD number:** 164152 - **SEC file number:** 802-78731 - **Registration status:** Registered - **Reports private funds:** Yes - **IAPD record:** https://adviserinfo.sec.gov/firm/summary/164152 ## About Lumira Ventures is a venture capital firm focused on healthcare and IT innovation. The firm invests in innovative technologies and emerging health technologies. It operates a VIP program that provides venture capital experience and toolkit support to participants. ## Sectors - Biotech - Digital Health - Pharmaceuticals - Medical Devices ## People - Peter van der Velden — Managing General Partner ## Questions ### Who runs investment decisions at Lumira Ventures? Managing General Partner Peter van der Velden leads the investment team. Lumira operates a partnership structure where senior partners with scientific, clinical, or operating backgrounds share decision-making authority. The firm has not publicly disclosed a formal investment committee roster, but its organizational model reflects a consensus-driven partnership rather than a single-decision-maker structure. ### Does Lumira Ventures focus exclusively on Canadian companies? No. While roughly two-thirds of historical deployment has targeted Canadian-headquartered biotech and medical-device companies, Lumira also invests in US-based life sciences firms, particularly in Boston and San Francisco. The firm co-invests regularly with US crossover and specialist healthcare funds in syndicated rounds that span both geographies. ### Is Lumira Ventures a fund-of-funds or does it invest directly? Lumira invests directly in portfolio companies. The firm does not operate a fund-of-funds program. It structures its own general-partner vehicles, raises limited-partner commitments from institutional investors, and deploys capital directly into private life sciences companies spanning preclinical through late-clinical-stage development. ### What is Lumira's known posture on co-investments alongside external GPs? Lumira regularly co-invests alongside US healthcare specialist funds — confirmed syndicate partners include OrbiMed and venBio — particularly in crossover rounds that precede an IPO or acquisition. The firm's ability to lead rounds in Canadian companies while participating as a syndicate member in US deals reflects a flexible allocation approach that has produced multiple exits to large-cap pharmaceutical acquirers. ### Has Lumira Ventures produced notable exits? Yes. Fusion Pharmaceuticals, a radiopharmaceutical company Lumira backed from its early stages, was acquired by AstraZeneca for approximately $2.4B in 2024 (per the company, March 2024). The broader portfolio has generated multiple public listings including Milestone Pharmaceuticals, and the firm reports its portfolio companies have collectively created over $40B in public-market equity value. ### What investment stages does Lumira Ventures typically target? Lumira deploys across the full life-sciences continuum. The firm creates companies at the preclinical stage through its academic-sourcing network, then continues investing through clinical proof-of-concept, Series A and B rounds, and into late-stage crossover financings. Its latest fund, Lumira Ventures IV, closed at $255M in February 2024 with a mandate spanning this stage breadth. ## Related profiles - [Luminous Ventures](https://altss.com/profile/luminous-ventures) - [Lumir Ventures](https://altss.com/profile/lumir-ventures) --- Last updated: 2026-07-10T07:47:04.000Z Canonical page: https://altss.com/profile/lumira-ventures Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology